by Gus Iversen
, Editor in Chief | March 29, 2021
From the March 2021 issue of HealthCare Business News magazine
Looking ahead, the technological roadmap of IBA is focused on three areas: motion management, arc therapy and flash irradiation. The company currently has 36 centers treating patients in 86 rooms, and another 20 centers in development.
RefleXion announces multi system agreement with integrated proton solutions
RefleXion Medical, a therapeutic oncology company pioneering biology-guided radiotherapy (BgRT) as a new modality for treating all stages of cancer, announced in November its first multi-system contract with Integrated Proton Solutions (IPS), a provider of turn-key proton therapy programs in the U.S. The multi-year, multi-site contract will create centers that house both of these advanced approaches to external beam radiotherapy (EBRT) for treating malignant tumors.
Quest Imaging Solutions provides all major brands of surgical c-arms (new and refurbished) and carries a large inventory for purchase or rent. With over 20 years in the medical equipment business we can help you fulfill your equipment needs
"IPS looks forward to adding biology-guided radiotherapy to our armamentarium of therapeutic offerings, as we expect it to bring the efficacy of radiotherapy so often seen in early-stage cancer to late-stage or metastatic disease," said Jeff Bordok, CEO of IPS. "Other radiotherapy machines cannot efficiently treat multiple, moving tumors on one patient, and then be used for single-tumor treatment on the next patient. This eventual flexibility of the RefleXion machine makes it a clear winner in our view."
The RefleXion X1 machine with BgRT is designed to overcome the technical limitations that restrict radiotherapy to one or two tumors. Instead, aims to one day allow radiotherapy to reach more tumors during the same treatment session, even those tumors that move due to patient motion, such as breathing or digestion.
C-RAD receives order for three proton cancer treatment centers in the US
C-RAD announced in December that it had been selected as the partner to implement surface tracking technology for three proton cancer treatment centers in the US.
C-RAD offers a specific version of its Catalyst System for use in proton and particle therapy - Catalyst PT. It is based on the patented Catalyst technology and software as well as the hardware are tailored for the application in this environment.
The Catalyst system is delivered with the complete software suite with modules for Respiratory Gating, Patient Setup and Positioning and Motion Monitoring. The C-RAD SIGRT solution provides a continuous monitoring of the patient during a treatment fraction. The system is delivered with interfaces that allow to interrupt the treatment beam if patient motion is above a clinically defined threshold.